Nörosarkoidoz ve Tedavisi

Wessendorf TE, Bonella F, Costabel U. Diagnosis of Sarcoidosis. Clinical Reviews in Allergy and Immunology. 2015;49(1):54–62. doi:10.1007/s12016-015-8475-x

Bokhari SRA, Zulfiqar H, Mansur A. Sarcoidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430687/

Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of Sarcoidosis 1946–2013: A Population-Based Study. Mayo Clinic Proceedings. 2016;91(2):183–8. doi:10.1016/j.mayocp.2015.10.024

Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America: Analysis based on health care use. Annals of the American Thoracic Society. 2016;13(8):1244–52. doi:10.1513/AnnalsATS.201511-760OC

Bradshaw MJ, Pawate S, Koth LL, et al. Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment. Neurology Neuroimmunology & Neuroinflammation. 2021;8(6):e1084. doi:10.1212/NXI.0000000000001084

Seltzer S, Mark AS, Atlas SW. CNS sarcoidosis: Evaluation with contrast-enhanced MR imaging. American Journal of Neuroradiology. 1991;12(6):1227–33.

Shen J, Lackey E, Shah S. Neurosarcoidosis: Diagnostic Challenges and Mimics—A Review. Current Allergy and Asthma Reports. 2023;23(5):399–410. doi:10.1007/s11882-023-01069-1

Lacomis D. Neurosarcoidosis. Current Neuropharmacology. 2011;9(3):429–36. doi:10.2174/157015911796557984

Ohno T, Ishihara M, Shibuya E, et al. Sarcoid uveitis in a patient with multiple neurological lesions: A case report and review of the literature. Journal of Medical Case Reports. 2018;12:301. doi:10.1186/s13256-018-1823-1

Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: Systematic review and meta-analysis. BMC Neurology. 2016;16:220. doi:10.1186/s12883-016-0741-x

Nwebube CO, Bou GA, Castilho AJ, et al. Facial nerve palsy in neurosarcoidosis: clinical course, neuroinflammatory accompaniments, ancillary investigations, and response to treatment. Journal of Neurology. 2022;269(10):5328–36. doi:10.1007/s00415-022-11080-6

Stern BJ, Krumholz A, Johns C, et al.. Sarcoidosis and its neurological manifestations. Archives of Neurology. 1985;42(9):909–17. doi:10.1001/archneur.1985.04060090095022

Makimoto G, Kawakado K, Nakanishi M, et al. Heerfordt’s syndrome associated with trigeminal nerve palsy and reversed halo sign. Internal Medicine. 2021;60(11):1747–52. doi:10.2169/internalmedicine.6073-20

Chaubey M, Meena K, Singh T, et al. Neurosarcoidosis: An under-diagnosed cause of myelopathy. Journal of Family Medicine and Primary Care. 2024;13(5):2157–60. doi:10.4103/jfmpc.jfmpc_173_24

Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology. 2018;90(1):e96–e102. doi:10.1212/WNL.0000000000004781

Barreras P, Fitzgerald KC, Mealy MA, et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology. 2018;90(1):E12–21. doi:10.1212/WNL.0000000000004765

Sohn M, Culver DA, Judson MA, et al. Spinal cord neurosarcoidosis. The American Journal of the Medical Sciences. 2014;347(3):195–8. doi:10.1097/MAJ.0b013e3182808781

Soni N, Bathla G, Pillenahalli Maheshwarappa R. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiology Journal. 2019;32(1):17–28. doi:10.1177/1971400918806634

Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology. 2016;79(3):437–47. doi:10.1002/ana.24582

Carlson ML, White JR, Espahbodi M, et al. Cranial base manifestations of neurosarcoidosis: A review of 305 patients. Otology & Neurotology. 2015;36(1):156–66. doi:10.1097/MAO.0000000000000643

Chakales PA, Herman MC, Chien LC, et al. Pachymeningitis in Biopsy-Proven Sarcoidosis: Clinical Course, Radiographic Findings, Response to Treatment, and Long-term Outcomes. Neurology Neuroimmunology & Neuroinflammation. 2022;9:e200036. doi:10.1212/NXI.0000000000200036

Bathla G, Watal P, Gupta S, et al. Cerebrovascular manifestations of neurosarcoidosis: An underrecognized aspect of the imaging spectrum. American Journal of Neuroradiology. 2018;39(6):1194–200. doi:10.3174/ajnr.A5586

Pirau L, Lui F. Neurosarcoidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441901/

Nozaki K, Judson MA. Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. La Presse Médicale. 2012;41(6 Pt 2):e331–48. doi:10.1016/j.lpm.2012.03.015

Said G, Lacroix C, Planté-Bordeneuve V, et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: A clinicopathological study of 11 patients. Brain. 2002;125(2):264–75. doi:10.1093/brain/awf020

Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. The Lancet. 2002;359(9323):2085–6. doi:10.1016/S0140-6736(02)08929-5

Anthony J, Esper GJ, Ioachimescu A. Hypothalamic–pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review. Pituitary. 2016;19(1):19–29. doi:10.1007/s11102-015-0671-1

Ungprasert P, Crowson CS, Matteson EL. Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976–2013. Neuroepidemiology. 2017;48(2):87–94. doi:10.1159/000477146

Berntsson SG, Elmgren A, Gudjonsson O, et al. A comprehensive diagnostic approach in suspected neurosarcoidosis. Scientific Reports. 2023;13(1):1–9. doi:10.1038/s41598-023-45678-9

Bridel C, Courvoisier DS, Vuilleumier N, et al. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. Journal of Neuroimmunology. 2015;285:1–3. doi:10.1016/j.jneuroim.2015.05.005

Ungprasert P, Carmona EM, Crowson CS, et al. Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study. Lung. 2016;194(1):91–5. doi:10.1007/s00408-015-9816-0

Smith JK, Matheus MG, Castillo M. Imaging Manifestations of Neurosarcoidosis. American Journal of Roentgenology. 2004;182(2):289–95. doi:10.2214/ajr.182.2.1820289

Chen X, Xu X, Chrysikos S, et al. Value of 18F-FDG PET/CT in differential diagnosis of sarcoidosis and lung cancer. Translational Lung Cancer Research. 2022;11(9):1926–35. doi:10.21037/tlcr-22-519

Vender RJ, Aldahham H, Gupta R. The role of PET in the management of sarcoidosis. Current Opinion in Pulmonary Medicine. 2022;28(5):485–91. doi:10.1097/MCP.0000000000000903

Voortman M, Drent M, Baughman RP. Management of neurosarcoidosis: A clinical challenge. Current Opinion in Neurology. 2019;32(4):475–83. doi:10.1097/WCO.0000000000000710

Eurelings LEM, Miedema JR, Dalm VASH, et al. Soluble IL-2 receptor for diagnosing sarcoidosis. PLOS ONE. 2019;14(10):e0223897. doi:10.1371/journal.pone.0223897

Spencer TS, Campellone JV, et al. Clinical and MRI manifestations of neurosarcoidosis. Seminars in Arthritis and Rheumatism. 2005;34(5):649–61. doi:10.1016/j.semarthrit.2004.12.004

Gullapalli D, Phillips LH. Neurologic manifestations of sarcoidosis. Neurologic Clinics. 2002;20(1):59–83. doi:10.1016/S0733-8619(03)00054-9

Ullapalli D, Phillips LH. Neurosarcoidosis. Current Neurology and Neuroscience Reports. 2004;4(6):441–7. doi:10.1007/s11910-004-0066-9

Scott TF, Yandora K, Valeri A, et al. Aggressive therapy for neurosarcoidosis. Archives of Neurology. 2007;64(5):691–6. doi:10.1001/archneur.64.5.691

Ungprasert P, Ryu JH, Matteson EL. Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis. Mayo Clinic Proceedings Innov Qual Outcomes. 2019;3(3):358–75. doi:10.1016/j.mayocpiqo.2019.04.006

Yasir M, Sonthalia S. Corticosteroid Adverse Effects. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/

Lower EE, Broderick JP, Brott TG, et al. Neurological sarcoidosis. Archives Internal Medicine. 1997;157(16):1864–8. doi:10.1001/archinte.1997.00440370070008

Kwon S, Judson MA. Clinical Pharmacology in Sarcoidosis. Journal of Clinical Medicine. 2024;13(1):24. doi:10.3390/jcm13010024

Baughman RP, Valeyre D, Korsten P, et al. ERS guidelines on sarcoidosis treatment. European Respiratory Journal. 2021;58(6):2004079. doi:10.1183/13993003.04079-2020

Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in sarcoidosis. CHEST. 2013;144(3):805–12. doi:10.1378/chest.12-1728

Petri M. Pregnancy and SLE. Best Practice & Research Clinical Obstetrics Gynaecology. 2020;64:24–30. doi:10.1016/j.bpobgyn.2019.09.002

Resman-Targoff BH. Systemic lupus erythematosus. In: DiPiro JT, et al. DiPiro’s Pharmacotherapy. 12th ed. New York: McGraw-Hill; 2023.

Marmor MF, Kellner U, Lai TYY, et al. Screening for hydroxychloroquine retinopathy. Ophthalmology. 2016;123(6):1386–94. doi:10.1016/j.ophtha.2016.01.058

Sammaritano LR, Bermas BL, et al. ACR guideline for reproductive health. Arthritis & Rheumatology. 2020;72(4):529–56. doi:10.1002/art.41191

Zissel G, Müller-Quernheim J. Immunopathogenesis of sarcoidosis. Respiratory Medicine. 1998;92(2):126–39. doi:10.1016/S0954-6111(98)90001-0

Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014;31(1):46–54.

Sinha T, Tahir S, Namal F, et al. Neurosarcoidosis: diagnosis and management. Cureus. 2024;16(9):e69208. doi:10.7759/cureus.69208

Hilezian F, Maarouf A, Boutiere C, et al. TNF-α inhibitors in CNS sarcoidosis. Journal of Neurology, Neurosurgery & Psychiatry. 2021;92(8):890–6. doi:10.1136/jnnp-2020-325665

Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for CNS sarcoidosis. Neurology. 2017;89(20):2092–100. doi:10.1212/WNL.0000000000004644

Zella S, Kneiphof J, Haghikia A, et al. Rituximab in probable neurosarcoidosis. Therapeutic Advances in Neurological Disorders. 2018;11:1756286418805732. doi:10.1177/1756286418805732

Menninger MD, Amdur RJ, Marcus RB. Role of radiotherapy in neurosarcoidosis. American Journal of Clinical Oncology. 2003;26(4):e115–8. doi:10.1097/01.COC.0000077933.69101.5D